MedTrace Logo

Effect of Short-term Prednisone Therapy on C-reactive Protein in Patients With Acute Heart Failure

NCT05916586 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2025-09-15

No results posted yet for this study

Summary

This is a multicenter, parallel-group, randomized, open-label, controlled trial. Patients with a diagnosis of acute heart failure (AHF) in the emergency department (ED) or after emergency presentation to hospital will be screened and informed of the study. After signed consent, patients will be randomized into the control group (usual AHF treatment) or intervention group (usual AHF treatment + prednisone). Prednisone will be given for 7 days. Patients will be assessed at days 2, 4 or at discharge if earlier, and at day 7 at hospital visit. If the patient has been discharged before day 7, a follow-up visit will be scheduled at day 7 for endpoints assessment followed by a scheduled hospital visit at day 31 and a telephone follow-up at day 91. Study drug will be dispensed for the patient to take home until day 7.

Conditions

  • Acute Heart Failure

Interventions

DRUG

Prednisone

Prednisone 40 mg orally once a day for 7 days

Sponsors & Collaborators

  • Heart Initiative

    lead OTHER

Principal Investigators

  • Yonathan Freund, MD · Emergency Department, Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-11
Primary Completion
2024-04-21
Completion
2024-07-08

Countries

  • Armenia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05916586 on ClinicalTrials.gov